Formulation, Design, Optimization, and Characterization of Novel Long-acting Injectable Dosage Form of Anti-Psychotic Drug

The current research aimed to create and analyze a new long-acting Brexpiprazole (BRX) injectable for successful anti-psychotic drug therapy in order to decrease dosage frequency and increase patient compliance. Systems for drug transport to particular body sites or regulating release rates with accuracy are known as drug delivery systems (DDS). By affixing the drug to a carrier particle like liposomes, nanoparticles, microspheres, etc., which modifies the drug's absorption and release properties, using carrier technology, drugs may be delivered in an intelligent manner. Utilizing Resomer RG 502 H and RESOMER® RG 752 H extended-release Polymer, Using a quasi-emulsion solvent diffusion, microspheres were made, and emulsification and solvent evaporation process. The produced microspheres were assessed for stability tests, in vitro drug release, flow characteristics, and drug entrapment efficiency. FTIR experiments were used to establish how well the drug excipients worked together. The acarbose microspheres that were created had an 89.9 to 96.1 percent drug entrapment efficiency. The impact of factors like polymer content on medication release was studied. The Stability study of the formulation was carried out under different conditions, and data were established. Comparative pharmacokinetic studies between marketed oral formulation and Brexpirazole microsphere test formulations in Wistar/SD Rats were carried out and concluded. Brexpiprazole (BRX) novel long-acting injectable formulation, could be used effectively for the treatment of mentally challenged anti-psychotic patients worldwide. The acarbose microspheres that were created had an 89.9 to 96.1 percent drug entrapment efficiency. The impact of factors like polymer content on medication release was studied. The Stability study of the formulation was carried out under different conditions and data were established. Comparative pharmacokinetic studies between marketed oral formulation and Brexpirazole microsphere test formulations in Wistar/SD Rats were carried out and concluded. Based on Literature data and drug excipients compatibility polymers were selected for manufacturing of extended release brexpiprazole microsphere Formulation. Preliminary formulation trial batches were taken with different polymers and studied for Drug Entrapment Efficiency and In Vitro release of drugs. Drug entrapment efficiency data of all the formulations are found satisfactory. In vitro, release results are compared with each formulation and based on the data, trial batch B1 with RESOMER® RG 502 H Poly(D,L-lactide-co-glycolide) 50:50 polymer and trial batch B2 with RESOMER® RG 752 H Poly(D,L-lactide-co-glycolide) 75:25 polymer have satisfactory results. So based on the study RESOMER® RG 502 H Poly(D,L-lactide-co-glycolide) 50:50 and RESOMER® RG 752 H Poly(D,L-lactide-co-glycolide) 75:25 were selected for Polymer Concentration and Formulation optimization study. The formulation is kept in the stability at different conditions and based on the data, the formulation is robust and all the derived values are found satisfactory. The comparative pharmacokinetic study was performed using oral marketed formulation and Brexpiprazole microsphere formulation. Based on the data we can conclude that long-acting depot formulations for administration of Brexpiprazol microsphere may offer no first-pass effect, increased bioavailability, fewer fluctuations in blood concentration and time, less dosing frequency, less no gastrointestinal intolerance, noninvasiveness.